Prof. Giancarlo Valori has written an enlightening book on the peoples, cultures and civilizations around the Mediterranean – from ancient times to the present – that provide the reader with a sweeping account of the riveting chapters of its history.

The Next Evolution Of Solar

By Jeff Siegel

In the past, we've discussed potential moves in the field of organic photovoltaics.

This is what many researchers are looking to as the next evolution of solar.

But after attending the Organic Photovoltaics conference in Philadelphia last week, I suspect it might be some time before we see any solid plays in this area.

Organic photovoltaics (OPV) offers the promise of significant disruption in pricing and aesthetics, as well as impressive efficiencies in low light conditions. OPV materials are also flexible and form-fitting. This stuff can potentially be wrapped around or even painted onto various materials.

Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today that its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, will host a conference call to discuss the Company's quarterly results for the period ending March 31, 2008. The call will be held Wednesday, May 14, 2008 at 8:30 a.m. EDT.

The Company invites all interested parties to participate. The call will be web cast and accessible live through the following URL: http://ir.javelinpharmaceuticals.com/events.cfm. The call will be archived on the Company's website www.javelinpharmaceuticals.com.

CONFERENCE CALL ALERT

Javelin Pharmaceuticals, Inc. Q1 2008 Earnings Call

Date: May 14, 2008

Time: 8:30 a.m. E.D.T.

Please dial: (877) 604-9667 or International (719) 325-4895

About Javelin Pharmaceuticals, Inc.

Please Note: ActiveX Windows Media Player plug-in required for video playback.

Direct link to video available here.

Welcome to Nanotech Today at InTimeTV.com. Nanotech Today is hosted by Ogan Gurel, MD/MPhil and combines two 21st century technologies – internet TV and nanotech – to communicate globally advances and trends in Nanotechnology worldwide.

This week's episode of Nanotech Today features Hooman Mohseni PhD, Assistant Professor of Electrical Engineering & Computer Sciences - Northwestern University

By Lumos Labs Science Associate, Paul Li, MS Neuroscience.

There is some new evidence that Alzheimer’s disease is much more likely for people whose parents both have the neurodegenerative disorder than if only one parent has it. Researchers examined families in which both parents have Alzheimer’s, and found that their children ended up with the disease 42% of the time.

Javelin Pharmaceuticals, Inc. (Amex: JAV - News), a leading developer and marketer of specialty pharmaceutical products for pain management, has received commitments from selected investors to purchase up to 11,450,000 shares of its common stock at a purchase price of $2.41 per share.

The purpose of the offering is to enhance our balance sheet as we proceed in our ongoing partnership discussions.

Certain officers and directors of Javelin will participate in this offering.

The closing of the offering is expected to take place on May 13, 2008, subject to customary closing conditions. The total number of shares to be sold in the offering are up to 11,450,000 with the gross proceeds of up to $27.6 million. The company estimates that net proceeds from the offering will be approximately $25.7 million, after deducting placement agent fees and estimated offering expenses.

By Elwin Green, Pittsburgh Post-Gazette

A biofuels developer is building a plant in Westmoreland County to demonstrate a process for producing ethanol from biomass and waste products.

Executives from Coskata, based in Warrenville, Ill., are joining Gov. Ed Rendell; Sen. Robert P. Casey Jr., D-Pa.; and Rep. Tim Murphy, R-Upper St. Clair, at the David L. Lawrence Convention Center this morning to announce the $25 million project in Madison.

The plant, which will be on the grounds of the Westinghouse Plasma Center, will employ about 20 to produce ethanol from a variety of materials, including municipal waste, more cheaply and efficiently than producing it from corn, said Bill Roe, Coskata's president and chief executive officer, in an interview with the Post-Gazette.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News), announced today that it has fully enrolled its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer.

This open label trial is evaluating the safety and efficacy of Curaxin CBLC102 for use in treating patients with hormone-refractory metastatic prostate cancer. Curaxins have multiple mechanisms of action, including simultaneous activation of p53 and inhibition of NF-kappaB, which are frequently deregulated in cancer. Compounds that target p53 or NF-kappaB independently have been validated as cancer therapies; however, Curaxins are the only compounds currently known to CBLI that simultaneously target both pathways.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that Buyins.net initiated coverage on the Company after releasing the latest short sale data through May 2008.

The Buyins.net report stated that the total aggregate number of CBLI shares shorted between July 2006 and May 2008 is approximately 2.5 million shares. The report also stated that the CBLI SqueezeTrigger price of $7.41 is the volume weighted average short price of all short selling in CBLI.

Visual Management Systems, Inc. (OTC BB:VMSY.OB - News), a leading digital surveillance company based in Toms River, N.J., is pleased to announce that CEO Jason Gonzalez was recently interviewed by Zangani Investment Community.

In the interview Mr. Gonzalez discusses Visual Management Systems and its recent acquisitions of the assets of the Intelligence Digital Systems.

The interview can be accessed in its entirety at: http://www.zangani.com/webcasts/20080505/vms.

Zangani Investor Community interviews Jason Gonzalez, Chief Executive Officer of Visual Management Systems (VMS). Jason discusses the company's recent acquisition of substantially all the assets of Intelligent Digital Systems, LLC., a leading enterprise surveillance software development company and manufacturer of the TechEye® Line of Network and Digital Video Recording Devices.

Visual Management Systems, Inc. (OTCBB: VMSY) is a New Jersey Based Corporation that consolidates the operations of subsidiaries including Visual Management Systems, LLC and Visual Management Systems PDG, LLC. The VMS Companies focus on providing businesses with remote management systems for loss prevention, physical security, asset protection and management controls - on and off-site.

Milestone Payments slated for reduction from $25 Million to $7 Million, Royalties from 10-12% to 4%

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News), today announced an agreement with BioAxone Therapeutic, Inc., of Montreal, Canada, whereby, upon payment by Alseres of an option fee of $7 million on or before October 27, 2008, Alseres may exercise an option to amend the Company's Cethrin License Agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Pursuant to the option agreement, the pre-commercial milestone payments in the amended license agreement will be reduced from $25 million to $7 million payable on or before December 31, 2009. In addition, the sales-based royalties in the amended license agreement will be reduced from 10-12% to 4% for spinal cord injury and 1% for all other indications. Finally, the amended license agreement will eliminate all development milestones related to Cethrin.

UTEK Corporation (AMEX:UTK - News) (LSE-AIM:UTK) today announced financial
results for the three months ended March 31, 2008.

Results of Operations

For the quarter ended March 31, 2008, income from operations (revenue)
was $3,665,566 as compared to $7,947,771 for March 31, 2007. Net income
(loss) from operations for the quarter ended March 31, 2008 was
($378,399), as compared to $2,233,391 for the quarter ended March 31,
2007. Approximately 72% and 88% of our income from operations (revenue)
was received in the form of unregistered shares of stock for the
quarters ended March 31, 2008 and 2007, respectively.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News) today announced that the Company will participate in a panel entitled "Traumatic Brain and Spinal Cord Injury" at the Neurotech Industry Investing & Partnering Conference in Boston, MA, Thursday, May 8, 2008. The session will focus on emerging treatments of major traumatic injuries to the Central Nervous System (CNS). The event is the premier partnering and investing conference for the segment of the healthcare sector focused on neurological technologies.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that the Company has been featured in "Gene Marcial's 7 Commandments of Stock Investing," recently published by FT Press. Gene Marcial is a senior writer and columnist at BusinessWeek where he writes the column "Inside Wall Street."

Cleveland BioLabs was cited as one of "several little-known biotechs that have outscored their peers" under the chapter titled, "Commandment 6: Don't Fear The Unknown" of "Gene Marcial's 7 Commandments of Stock Investing." The chapter includes a brief summary by the author of Cleveland BioLabs' history and stock price from its IPO in July 2006 through early 2008.

Source: Green Chip Stocks

If you haven't been following the debate surrounding capping and trading emissions, you're missing out. Not only does it have implications for how our nation, and the world, produces energy, it has the potential to offer a myriad of opportunities for well-informed investors.

You see, California has been asking for permission to regulate greenhouse gas emissions since 2004, but the philistines at the Environmental Protection Agency (EPA) have yet to grant it permission to do so.

UTEK Corporation (AMEX:UTK - News)(LSE-AIM:UTK) today announced that it will report its financial results for the first quarter 2008 on Tuesday, May 6, 2008. UTEK will hold a live conference call at 10:00 a.m. EDT to discuss the results. All interested parties are invited to attend the conference call.'

US & Canada: 866-672-2663
UK: 0-800-032-3836
Other International Callers: 973-582-2772
Please reference conference ID# 45897390

UTEK Corporation (AMEX:UTK - News) (LSE-AIM:UTK), a leading Innovation services company, is pleased to announce that its subsidiary UTEK Real Estate Holdings, Inc., has executed a lease with WilsonMiller, Inc. for approximately 8,000 square feet in UTEK’s office center.

“We are very pleased to have WilsonMiller as a tenant, and we look forward to a long term, mutually beneficial relationship. The consummation of this lease brings UTEK’s office center to 100% occupancy,” said Sam Reiber, President of UTEK Real Estate Holdings, Inc.